AlphAIAlphAI — Financial news for AI agents
stocktitan.net$LFCR

Lifecore Biomedical Reports Financial Results for the Third Quarter Ended September 30, 2026, and Provides Corporate Update

Lifecore Biomedical (LFCR) reported Q3 2026 revenues of $25.3M, down 18.6% YoY. Net loss was $40.1M, or $1.08 per share. CEO Paul Josephs highlighted new business wins, including projects with top pharmaceutical and biotech companies, expected to contribute to long-term revenue growth. Adjusted EBITDA was $4.0M, up $1.0M YoY. The company ended Q3 with $38.0M in liquidity.

Original reporting
stocktitan.net
Published Nov 4, 2026, 12:05 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 4, 2026, 12:07 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefEarnings
Primary signal
$LFCR
Bearish
high confidence
Mentioned
$LFCR
Relevance
6/10
AlphAI data visualization · based on stocktitan.net
Decision brief

The 30-second read

$LFCRBearishMed
01

Why it matters

The Q3 earnings miss highlights execution challenges and may trigger short‑term sell pressure, but the announced pipeline wins could support longer‑term upside.

02

Market read

The earnings release provides fresh quantitative data that can influence trading decisions for LFCR and potentially its sector peers.

03

What to watch

Cash balance of $38M and a revolving credit facility provide liquidity cushion; cost reductions in operating expenses may improve margins later.

Relevance 6/10Novelty 7/10Timing: released today

Background

Lifecore Biomedical is a Nasdaq‑listed CDMO focused on sterile injectable products for biotech and pharma customers.

Company-level read

Ticker impact

$LFCRBearishHigh confidence
Context

Lifecore Biomedical reported Q3 2026 results showing an 18.6% revenue decline to $25.3M and a net loss of $40.1M.

Expected impact

downward pressure as investors digest weaker revenue and larger loss

Evidence & confidence

The disclosed decline in revenue and sharp increase in net loss are material new information that typically depresses share price.

Market effects

Sector

Signals softness in the CDMO sector, potentially affecting peers with similar exposure to biotech contract work.

Regional

Limited to U.S. biotech and contract manufacturing investors.

Global

Minimal; primarily a micro‑cap earnings event.

Counterpoint

What could challenge this read

If the new technology transfer projects materialize in 2027, the stock could be undervalued despite the near‑term loss.

Key entities

  • Company
    Lifecore Biomedical

    NASDAQ: LFCR, contract development and manufacturing organization.

Read at source← All news

Related articles

$LFCRHigh

Lifecore Biomedical, Inc. entered into an Agreement and Plan of Merger with Lifecore Inc. and Hazel Merger Sub, Inc. providing for the merger of Merger Sub…

LIFECORE BIOMEDICAL, INC. \DE\ (LFCR) filed an SEC Form 8-K — Other Events. Item 8.01 Other Events. As previously disclosed, on September 27, 2026, Lifecore Biomedical, Inc. (the “Company”) entered into an Agreement and Plan of Merger (the “Merger Agreement”) with Lifecore Inc. (“Parent”) and Hazel Merger Sub, Inc. (“Merger Sub”) providing for the merger

SEC EDGAR 8-K
$LFCRMed

Lifecore Biomedical Reports Financial Results for the Third Quarter Ended September 30, 2026, and Provides Corporate Update

LIFECORE BIOMEDICAL, INC. \DE\ (LFCR) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Lifecore Biomedical Reports Financial Results for the Third Quarter Ended September 30, 2026 , and Provides Corporate Update -- Multiple New Business Wins Continue to Strengthen Growing Pipeline -- CHASKA, Minn., November 4, 2026 -- Lifecore Biomedical, Inc. (NASDAQ:

SEC EDGAR 8-K
$LFCRMed

Lifecore Biomedical, Inc. entered into an Agreement and Plan of Merger with Lifecore Inc. and Hazel Merger Sub, Inc. On October 16, 2026, the Board of…

LIFECORE BIOMEDICAL, INC. \DE\ (LFCR) filed an SEC Form 8-K — Other Events. Item 8.01 Other Events. As previously disclosed, on September 27, 2026, Lifecore Biomedical, Inc. (the “Company”) entered into an Agreement and Plan of Merger (the “Merger Agreement”) with Lifecore Inc. and Hazel Merger Sub, Inc. On October 16, 2026, the Board of Directors (the “

SEC EDGAR 8-K
$HRLMedAI 8/10

Deal Dispatch: Hormel Acquires Brakebush, Onsemi buys Synaptics for $5.7 Billion, Leslie’s Pools Bankrupt

Hormel (HRL) acquires Brakebush for $1.06B; Onsemi (ON) to buy Synaptics for $5.7B; Leslie's files for bankruptcy. Valley National (VLY) to acquire Bluevine for $340M. Yext (YEXT) to acquire Flamel.ai. Lifecore (LFCR) to be acquired by Webster Equity for up to $663.7M. SoftBank completes DigitalBridge acquisition. GBTG acquired by Long Lake for $6.3B.

benzinga.com